Plain-English translation of NCT07057674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing HS-20094, a new injectable medication designed to help with weight management in adults who are overweight or obese. Researchers want to confirm that two different pen designs — one that holds a single dose and one that holds multiple doses — deliver the same amount of medication into your body. Both pens work the same way: you give yourself an injection under the skin once per week.
Before this medication can be approved for widespread use, the manufacturer needs to prove that both delivery designs work equally well. This study makes sure patients get consistent, reliable treatment regardless of which pen design they receive.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the single-dose or multi-dose pen version of the medication. Both groups will give themselves an injection under the skin once each week for the study duration. You'll attend clinic visits for blood tests and health checks to monitor how the medication works and to ensure your safety. The study involves careful tracking of your response to the treatment and any side effects you experience.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Enrollment target
~144 participants
Started
April 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yu Cao
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.